SBRT Noninferior to Conventional RT for Intermediate-Risk Prostate Cancer
SAN DIEGO — Stereotactic body radiation therapy (SBRT) was as effective as conventional radiation therapy (CRT) in treating intermediate-risk prostate cancer, according to results from the randomized PACE-B trial. Among 874 patients, those randomized to CRT had a biochemical/clinical failure-free rate of 94.6% versus 95.8% for those randomized to SBRT (HR 0.73, 90% CI 0.47-1.12, […]
SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer
SAN DIEGO — Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not suitable for surgery, according to the FASTRACK II trial. In the prospective, phase II study of 70 patients, none had local progression of kidney cancer during the trial lifetime (median […]
SBRT Added to Standard Tx Boosts Outcomes in Oligometastatic Prostate Cancer
Combining stereotactic body radiation therapy (SBRT) with standard systemic therapy yielded significant increases in the rates of biochemical response and progression-free survival (PFS) in patients with oligometastatic castrate-resistant prostate cancer (CRPC), the phase II randomized ARTO trial showed. In a cohort of 157 patients at 6 months after the start of treatment, biochemical response was […]
MR-Guided Adaptive SBRT Tied to Reduced Side Effects in Prostate Cancer
Magnetic resonance (MR)‐guided adaptive stereotactic body radiotherapy (SBRT) for prostate cancer was associated with significantly lower rates of acute genitourinary and gastrointestinal toxicities compared with CT-guided non-adaptive SBRT, according to a systematic review and meta-analysis. Across 29 prospective studies involving over 2,500 patients, the risk of short‐term genitourinary side effects was reduced by 44% with […]
MRI-Guided RT Reduced Acute Toxic Effects in Men With Localized Prostate Cancer
Stereotactic body radiotherapy (SBRT) guided by MRI for localized prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomized phase III MIRAGE trial. At 3-month follow-up, incidence of acute grade 2 or higher genitourinary toxic effects was 24.4% with MRI-guided SBRT versus 43.4% with […]
SABR for Oligometastatic Cancer Turns in ‘Acceptable’ Rates of Toxicity
Stereotactic ablative radiotherapy (SABR) treatment for oligometastatic or oligoprogressive cancer appeared to come with “acceptable” rates of toxic effects, according to SABR-5 study results. Among a population of 381 patients in the phase II trial, and with a median follow-up of 25 months, rates of grade 2 or greater toxic effects were observed in 18.6%, […]
Single- or Multi-Fraction SABR for Lung Oligometastases?
Both single-fraction and multifraction stereotactic ablative body radiotherapy (SABR) had acceptable safety and comparable efficacy for patients with pulmonary oligometastases, according to results from a phase II randomized trial. The primary endpoint of grade 3 or higher adverse events (AEs) related to treatment within 1 year of SABR was similar between the single-fraction arm (5%) […]